Key Highlights
- Loss per share was USD 0.21 against an estimate of a USD 0.35 loss.
- Net loss was USD 3.63 million, compared with USD 3.51 million.
- Research and development expenses were USD 207 thousand, against USD 570 thousand.
- Nine-month acquired in-process Research and Development was USD 22.18 million.
Tempest Therapeutics (NASDAQ:TPST) reported a third quarter 2026 loss per share of USD 0.21, against an estimate of a USD 0.35 loss and a USD 0.79 loss in the third quarter of 2025. The net loss was USD 3.63 million, compared with USD 3.51 million.
The loss from operations was USD 2.82 million, compared with USD 3.60 million. Amounts in the filing are presented in thousands.
Operating Expenses
Research and development expenses were USD 207 thousand, compared with USD 570 thousand, and general and administrative expenses were USD 2.62 million, compared with USD 3.03 million. There was no acquired in-process research and development in either third quarter.
The filing's loss per share is calculated for common stock, restricted stock units and pre-funded warrants on a combined basis, on a basic and diluted basis.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 36.57 million, compared with USD 22.24 million, and the loss per share was USD 2.54, compared with USD 5.71. The loss from operations was USD 35.79 million, compared with USD 22.50 million.
Research and development expenses for the nine months were USD 2.14 million, compared with USD 12.07 million, and general and administrative expenses were USD 11.47 million, compared with USD 10.43 million. The nine-month period included acquired in-process research and development of USD 22.18 million, with none in the prior-year period. Interest expense in the prior-year nine-month period was USD 207 thousand, with none in 2026.
Cash Flow Items and Balance Sheet
The filing's Cash Flow statement reports research and development expense funded by a related party contribution of services of USD 1.71 million, and acquired in-process research and development of USD 19.93 million as an adjustment to reconcile net loss to cash used in operations.
Total Assets were USD 8.76 million at September 30, 2026, compared with USD 16.93 million at the prior Balance Sheet date. The statement of stockholders' Equity shows a balance at March 31, 2026 of 14,344,034 shares of common stock, and describes an issuance of common stock for a Warrant inducement.
Share-based compensation in general and administrative expenses was USD 51 thousand for the quarter, compared with USD 52 thousand, and USD 155 thousand for the nine months, compared with USD 1.56 million.
The filing states that the company's most advanced program is TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate being evaluated in an ongoing Phase 1 dose-escalation study for relapsed or refractory multiple myeloma. It states that the company plans to evaluate TPST-4003 in an investigator-initiated trial in China in approximately 10 patients with myasthenia gravis or multiple sclerosis, and that it closed an asset Acquisition on February 3, 2026.
The filing also states that on August 13, 2026 the company entered into a purchase agreement that gives it the right, but not the obligation, to sell up to USD 25.0 million of its common stock to an investor, increasing to USD 50.0 million if the initial amount is sold, and that it had sold USD 0.3 million in gross proceeds as of September 30, 2026.
Tempest Therapeutics Q3 2026 Earnings: Key Takeaways
Tempest Therapeutics reported a third quarter 2026 loss per share of USD 0.21 and a net loss of USD 3.63 million. The nine-month net loss was USD 36.57 million, which included USD 22.18 million of acquired in-process research and development.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...